Recombinant CD137-Fc, its synthesis, and applications for improving the immune system functions, such as tumor immunotherapy and to reduce the inflammation due to the novel coronavirus.

Autor: Ajami M; Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran., Nazari M; Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran., Mahmoodzadeh H; Breast Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran., Moazzeni SM; Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Jazyk: angličtina
Zdroj: Journal of cellular biochemistry [J Cell Biochem] 2021 May 16. Date of Electronic Publication: 2021 May 16.
DOI: 10.1002/jcb.29928
Abstrakt: CD137 (ILA/4-1BB), a member of tumor necrosis factor receptor superfamily, is one of the most important T cell costimulatory molecules. Interaction of this molecule with its ligand transmits a two-way signal that activates both T lymphocyte and antigen presenting cells. The soluble form of CD137 (sCD137) reduces the activity of its membrane isoform and is associated with T lymphocyte activation-induced cell death. Recombinant CD137-Fc may be used to treat cancers, autoimmune disorders and viral infections. It may also be useful for management of coronavirus infection. The 1276 bp DNA sequence encoded CD137-Fc recombinant protein was prepared and subcloned into lentiviral vector and expressed in transduced CHO-K1 eukaryotic cells. The sodium dodecyl sulfate-polyacrylamide gel electrophoresis, Western blot analysis, and enzyme-linked immunosorbent assay analysis results demonstrated that the expression of the 70-kDa CD137-Fc molecule was detectable without any degradation. This study helps to confirm previous research suggesting the use of this recombinant protein as a promising solution for the treatment of virus infections. CD137-Fc fusion protein could also make immunotherapy more effective for some diseases. This product is widely used in novel medical treatments, including cell-based immunotherapy such as dendritic cell, CAR T and CAR NK therapy. Its production and usage in research and treatment is noticeable also in current coronavirus disease 2019 pandemic.
(© 2021 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: